Recent from talks
Betahistine
Knowledge base stats:
Talk channels stats:
Members stats:
Betahistine
Betahistine, sold under the brand name Serc among others, is an anti-vertigo medication. It is commonly prescribed for balance disorders or to alleviate vertigo symptoms. It was first registered in Europe in 1970 for the treatment of Ménière's disease, but current evidence does not support its efficacy in treating it.
Betahistine was once believed to have some positive effects in the treatment of Ménière's disease and vertigo, but more recent evidence casts doubt on its efficacy. Studies of the use of betahistine have shown a reduction in symptoms of vertigo and, to a lesser extent, tinnitus, but conclusive evidence is lacking at present.
Oral betahistine has been approved for the treatment of Ménière's disease and vestibular vertigo in more than 80 countries worldwide, and has been reportedly prescribed for more than 130 million patients. However, betahistine has not been approved for marketing in the United States for the past few decades, and there is disagreement about its efficacy.
The Cochrane Library concluded in 2001 that "Most trials suggested a reduction of vertigo with betahistine and some suggested a reduction in tinnitus but all these effects may have been caused by bias in the methods. One trial with good methods showed no effect of betahistine on tinnitus compared with placebo in 35 patients. None of the trials showed any effect of betahistine on hearing loss. No serious adverse effects were found with betahistine."
An intranasal formulation of betahistine dihydrochloride received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of obesity associated with Prader–Willi syndrome, a rare genetic disorder.
Betahistine is also undergoing clinical trials for the treatment of attention deficit hyperactivity disorder (ADHD).
Betahistine is contraindicated for patients with pheochromocytoma. Patients with bronchial asthma or a history of peptic ulcer need to be closely monitored.[citation needed]
Patients taking betahistine may experience the following adverse effects:
Hub AI
Betahistine AI simulator
(@Betahistine_simulator)
Betahistine
Betahistine, sold under the brand name Serc among others, is an anti-vertigo medication. It is commonly prescribed for balance disorders or to alleviate vertigo symptoms. It was first registered in Europe in 1970 for the treatment of Ménière's disease, but current evidence does not support its efficacy in treating it.
Betahistine was once believed to have some positive effects in the treatment of Ménière's disease and vertigo, but more recent evidence casts doubt on its efficacy. Studies of the use of betahistine have shown a reduction in symptoms of vertigo and, to a lesser extent, tinnitus, but conclusive evidence is lacking at present.
Oral betahistine has been approved for the treatment of Ménière's disease and vestibular vertigo in more than 80 countries worldwide, and has been reportedly prescribed for more than 130 million patients. However, betahistine has not been approved for marketing in the United States for the past few decades, and there is disagreement about its efficacy.
The Cochrane Library concluded in 2001 that "Most trials suggested a reduction of vertigo with betahistine and some suggested a reduction in tinnitus but all these effects may have been caused by bias in the methods. One trial with good methods showed no effect of betahistine on tinnitus compared with placebo in 35 patients. None of the trials showed any effect of betahistine on hearing loss. No serious adverse effects were found with betahistine."
An intranasal formulation of betahistine dihydrochloride received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of obesity associated with Prader–Willi syndrome, a rare genetic disorder.
Betahistine is also undergoing clinical trials for the treatment of attention deficit hyperactivity disorder (ADHD).
Betahistine is contraindicated for patients with pheochromocytoma. Patients with bronchial asthma or a history of peptic ulcer need to be closely monitored.[citation needed]
Patients taking betahistine may experience the following adverse effects:
Recent media